RESUMEN
Introducción: La adherencia al tratamiento con somatotropina se relaciona con el aumento de la velocidad de crecimiento y la mejora de la talla adulta. El objeto de este estudio es conocer la adherencia de pacientes en tratamiento con dispositivo electrónico y determinar la relación con diferentes variables (edad, sexo, duración del tratamiento, diagnóstico, talla y velocidad de crecimiento). Material y métodos: Estudio descriptivo, longitudinal y retrospectivo de menores de 14 años de la consulta de Endocrinología Pediátrica del Hospital General Universitario de Ciudad Real, en tratamiento con somatotropina administrada con el dispositivo electrónico Easypod(R). Se realiza seguimiento de la adherencia durante 12 meses. Se define adherencia según la fórmula: (días administrados a la dosis prescrita/días prescritos)×100. El análisis de los datos se realizó con el software SPSS. Resultados: Se recogió a 30 pacientes: predominio varones (57%), edad media 6,09 años, menores de 5 años el 51%. Las causas más frecuentes de tratamiento: pequeño para la edad gestacional (55%) y déficit de hormona de crecimiento (38%). Tiempo medio de tratamiento 4,3 años (3,6-5). Se evidenció una adherencia media del 92,3% (87,7-96,9), observándose una correlación significativa con la edad (R de Pearson = -0,384; p = 0,03) y la duración del tratamiento (R de Pearson = -0,537; p = 0,003). Conclusiones: La adherencia en nuestros pacientes con dispositivo electrónico es alta (92,3%), relacionándose inversamente con la edad y la duración del tratamiento. El uso de dispositivos electrónicos permite un seguimiento del cumplimiento terapéutico, lo que repercute en la optimización del tratamiento
Introduction: Adherence to somatotropin treatment is associated with increased growth velocity and improved adult height. The purpose of this study is to determine the adherence of patients undergoing treatment with an electronic device and its relationship with different variables (age, gender, duration of treatment, diagnosis, height, and growth rate). Material and methods: Descriptive, longitudinal and retrospective study of children less than 14 years of age undergoing treatment with somatotropin administered with the Easypod(R) electronic device in the Paediatric Endocrinology Outpatient Clinic of the General University Hospital of Ciudad Real, Spain. Adherence was monitored for 12 months and was defined according to the equation: (days administered at the prescribed dose / prescribed days)×100. The data analysis was performed using SPSS software. Results: Data were collected from 30 patients, with a predominance of males (57%), a mean age of 6.09 years, with 51% of children less than 5 years old. The most common reasons for the treatment were: small for gestational age (55%) and growth hormone deficiency (38%). The mean duration of treatment was 4.3 years (3.6-5). A mean adherence of 92.3% (87.7-96.9) was observed, and there was a significant correlation with age (Pearson R = -0.384, P=.03), and duration of treatment (Pearson R = -0.537; P=.003). Conclusions: The adherence in our patients with electronic device is high (92.3%), and is inversely associated with age and duration. The use of electronic devices allows monitoring of therapeutic compliance, which affects the optimisation of treatment
Asunto(s)
Humanos , Masculino , Femenino , Preescolar , Niño , Adolescente , Hormona de Crecimiento Humana/uso terapéutico , Cumplimiento de la Medicación/estadística & datos numéricos , Crecimiento/fisiología , Sistemas de Liberación de Medicamentos/métodos , Epidemiología Descriptiva , Estudios Retrospectivos , Estudios Longitudinales , Electrónica Médica/instrumentación , Electrónica Médica/métodos , Sistemas de Liberación de MedicamentosRESUMEN
INTRODUCTION: Adherence to somatotropin treatment is associated with increased growth velocity and improved adult height. The purpose of this study is to determine the adherence of patients undergoing treatment with an electronic device and its relationship with different variables (age, gender, duration of treatment, diagnosis, height, and growth rate). MATERIAL AND METHODS: Descriptive, longitudinal and retrospective study of children less than 14 years of age undergoing treatment with somatotropin administered with the Easypod® electronic device in the Paediatric Endocrinology Outpatient Clinic of the General University Hospital of Ciudad Real, Spain. Adherence was monitored for 12 months and was defined according to the equation: (days administered at the prescribed dose / prescribed days)×100. The data analysis was performed using SPSS software. RESULTS: Data were collected from 30 patients, with a predominance of males (57%), a mean age of 6.09 years, with 51% of children less than 5 years old. The most common reasons for the treatment were: small for gestational age (55%) and growth hormone deficiency (38%). The mean duration of treatment was 4.3 years (3.6-5). A mean adherence of 92.3% (87.7-96.9) was observed, and there was a significant correlation with age (Pearson R = -0.384, P=.03), and duration of treatment (Pearson R = -0.537; P=.003). CONCLUSIONS: The adherence in our patients with electronic device is high (92.3%), and is inversely associated with age and duration. The use of electronic devices allows monitoring of therapeutic compliance, which affects the optimisation of treatment.
